getimage-48-768x274.png
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 16:01 ET | Capricor Therapeutics
Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0...
getimage-48-768x274.png
Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
May 13, 2020 16:30 ET | Capricor Therapeutics
LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological...
getimage-48-768x274.png
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
May 13, 2020 07:00 ET | Capricor Therapeutics
-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that Correlates Stabilization...
getimage-48-768x274.png
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
April 29, 2020 09:15 ET | Capricor Therapeutics
LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological...
getimage-48-768x274.png
Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
April 13, 2020 09:00 ET | Capricor Therapeutics
-To Provide Clinical Development Update on CAP-1002- -Final HOPE-2 Data Now Expected by Mid-Q2- LOS ANGELES, April 13, 2020 (GLOBE NEWSWIRE) --  Capricor Therapeutics (NASDAQ: CAPR) a...
getimage-48-768x274.png
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
April 03, 2020 08:00 ET | Capricor Therapeutics
­ -CAP-1002 Aims to Mitigate Severe Inflammatory Response Associated with COVID-19- -Expanded Access Protocol Submitted to FDA- LOS ANGELES, April 03, 2020 (GLOBE NEWSWIRE) -- Capricor...
getimage-48-768x274.png
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
March 24, 2020 08:00 ET | Capricor Therapeutics
LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
getimage-48-768x274.png
Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 18, 2020 16:01 ET | Capricor Therapeutics
-To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and Webcast Today at 4:30...
getimage-48-768x274.png
Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
March 17, 2020 08:00 ET | Capricor Therapeutics
LOS ANGELES, March 17, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
getimage-48-768x274.png
Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
March 11, 2020 16:30 ET | Capricor Therapeutics
LOS ANGELES, March 11, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...